Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective trial evaluating the safety and efficacy of Dianhydrogalactitol (VAL-083) in pediatric patients with medulloblastoma (MB) and high grade gliomas (HGG)

Next Previous
Trial Profile

A prospective trial evaluating the safety and efficacy of Dianhydrogalactitol (VAL-083) in pediatric patients with medulloblastoma (MB) and high grade gliomas (HGG)

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Oct 2023 According to a Kintara Therapeutics media release, company is suspending the development of VAL-083 based on the topline preliminary safety results from GBM AGILE trial.
  • 31 Oct 2023 Status changed from planning to suspended, according to Kintara Therapeutics media release.
  • 07 Sep 2016 According to Del Mar Pharmaceuticals media release,VAL-083 has received orphan drug designation in the U.S.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top